Impax Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Cuts Price Target on Impax Laboratories (IPXL) Following 2Q15
August 11, 2015 9:05 AM EDTLeerink Partners maintained a Market Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $47.00 (from $49.00), following its 2Q15 earnings report. IPXL reported revenue of $214m compared to the Street's $200m estimate. IPXL lowered its 2015 GM guidance, now in the low 50s (vs.... More
Impax Laboratories (IPXL) Misses Q2 EPS by 1c
August 10, 2015 6:46 AM EDTImpax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.34, $0.01 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $214.2 million versus the consensus estimate of $199.93 million.
For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.
... More